Clinical implications of DNA repair genetic alterations in cancer

Short Review
  • 43 Downloads

Summary

The overall prognosis of advanced cancer remains poor. Whilst accumulation of genetic mutations drives the cancerous phenotype, it is well known that DNA damaging lesions that lead to such mutations are predominantly monitored and repaired by the highly conserved DNA repair machinery in cells. Though chemotherapy as well as radiotherapy remains the mainstay of treatment, it is clear that the cancer cell's ability to respond to DNA damaging lesions induced by cytotoxic agents has a major bearing upon therapeutic efficacy and normal tissue toxicity. In this article we provide an overview on the role of DNA repair factors as prognostic/predictive markers with a specific focus on genetic alterations that confer altered DNA repair capacity in cells.

Keywords

DNA repair Chemotherapy Radiotherapy Polymorphisms 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, et al. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem, 73: 39–85, 2004PubMedCrossRefGoogle Scholar
  2. Gossage L, Madhusudan S. Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy. Mol Diagn Ther, 11: 361–380, 2007PubMedGoogle Scholar
  3. Shuck SC, Short EA, Turchi JJ. Eukaryotic nucleotide excision repair: from understanding mechanisms to influencing biology. Cell Res, 18: 64–72, 2008PubMedCrossRefGoogle Scholar
  4. Verbeek B, Southgate TD, Gilham DE, et al. O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy. Br Med Bull, 85: 17–33, 2008PubMedCrossRefGoogle Scholar
  5. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature, 411: 366–374, 2001PubMedCrossRefGoogle Scholar
  6. De la Torre C, Pincheira J, Lopez-Saez JF. Human syndromes with genomic instability and multiprotein machines that repair DNA double-strand breaks. Histol Histopathol, 18: 225–243, 2003PubMedGoogle Scholar
  7. Brookes AJ. The essence of SNPs. Gene, 234: 177–186, 1999PubMedCrossRefGoogle Scholar
  8. Patra SK, Patra A, Rizzi F, et al. Demethylation of (Cytosine-5-C-methyl) DNA and regulation of transcription in the epigenetic pathways of cancer development. Cancer Metastasis Rev, 27: 315–334, 2008PubMedCrossRefGoogle Scholar
  9. Vilmar A, Sorensen JB. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer, Epub ahead of print, 2008Google Scholar
  10. Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res, 58: 604–608, 1998PubMedGoogle Scholar
  11. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med, 355: 983–991, 2006PubMedCrossRefGoogle Scholar
  12. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol, 25: 2747–2754, 2007PubMedCrossRefGoogle Scholar
  13. Yu JJ, Lee KB, Mu C, et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol, 16: 555–560, 2000PubMedGoogle Scholar
  14. Gossage L, Madhusudan S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev, 33: 565–577, 2007PubMedCrossRefGoogle Scholar
  15. Benhamou S, Sarasin A. ERCC2/XPD gene polymorphisms and lung cancer: a HuGE review. Am J Epidemiol, 161: 1–14, 2005PubMedCrossRefGoogle Scholar
  16. Bobola MS, Finn LS, Ellenbogen RG, et al. Apurinic/apyrimidinic endonuclease activity is associated with response to radiation and chemotherapy in medulloblastoma and primitive neuroectodermal tumors. Clin Cancer Res, 11: 7405–7414, 2005PubMedCrossRefGoogle Scholar
  17. Bobola MS, Emond MJ, Blank A, et al. Apurinic endonuclease activity in adult gliomas and time to tumor progression after alkylating agent-based chemotherapy and after radiotherapy. Clin Cancer Res, 10: 7875–7883, 2004PubMedCrossRefGoogle Scholar
  18. Li D, Li Y, Jiao L, et al. Effects of base excision repair gene polymorphisms on pancreatic cancer survival. Int J Cancer, 120: 1748–1754, 2007PubMedCrossRefGoogle Scholar
  19. Hegi ME, Murat A, Lambiv WL, et al. Brain tumors: molecular biology and targeted therapies. Ann Oncol, 17(Suppl 10): x191–x197, 2006PubMedCrossRefGoogle Scholar
  20. Hamelin R, Chalastanis A, Colas C, et al. Clinical and molecular consequences of microsatellite instability in human cancers. Bull Cancer, 95: 121–132, 2008PubMedGoogle Scholar
  21. Bendardaf R, Lamlum H, Ristamaki R, et al. Mismatch repair status is a predictive factor of tumour response to 5-fluorouracil and irinotecan chemotherapy in patients with advanced colorectal cancer. Tumour Biol, 28: 212–220, 2007PubMedCrossRefGoogle Scholar
  22. Jover R, Zapater P, Castells A, et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut, 55: 848–855, 2006PubMedCrossRefGoogle Scholar
  23. Pors K, Patterson LH. DNA mismatch repair deficiency, resistance to cancer chemotherapy and the development of hypersensitive agents. Curr Top Med Chem, 5: 1133–1149, 2005PubMedCrossRefGoogle Scholar
  24. Maxwell JA, Johnson SP, McLendon RE, et al. Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clin Cancer Res, 14: 4859–4868, 2008PubMedCrossRefGoogle Scholar
  25. Scully R, Livingston DM. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature, 408: 429–432, 2000PubMedCrossRefGoogle Scholar
  26. James CR, Quinn JE, Mullan PB, et al. BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist, 12: 142–150, 2007PubMedCrossRefGoogle Scholar
  27. Byrski T, Gronwald J, Huzarski T, et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat, 108: 289–296, 2008PubMedCrossRefGoogle Scholar
  28. Wysocki PJ, Korski K, Lamperska K, et al. Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations. Med Sci Monit, 14: SC7–SC10, 2008PubMedGoogle Scholar
  29. Hennequin C, Quero L, Favaudon V. Determinants and predictive factors of tumour radiosensitivity. Cancer Radiother, 12: 3–13, 2008PubMedGoogle Scholar
  30. Fernet M, Hall J. Genetic biomarkers of therapeutic radiation sensitivity. DNA Repair (Amst), 3: 1237–1243, 2004CrossRefGoogle Scholar
  31. Chistiakov DA, Voronova NV, Chistiakov PA. Genetic variations in DNA repair genes, radiosensitivity to cancer and susceptibility to acute tissue reactions in radiotherapy-treated cancer patients. Acta Oncol, 47: 809–824, 2008PubMedCrossRefGoogle Scholar
  32. Ho AY, Atencio DP, Peters S, et al. Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Int J Radiat Oncol Biol Phys, 65: 646–655, 2006PubMedGoogle Scholar
  33. Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer, 8: 193–204, 2008PubMedCrossRefGoogle Scholar
  34. Madhusudan S, Hickson ID. DNA repair inhibition: a selective tumour targeting strategy. Trends Mol Med, 11: 503–511, 2005PubMedCrossRefGoogle Scholar
  35. Jones C, Plummer ER. PARP inhibitors and cancer therapy – early results and potential applications. Br J Radiol, 81(1): S2–S5, 2008PubMedCrossRefGoogle Scholar
  36. Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol, 8: 363–369, 2008PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Academic Unit of Oncology, School of Molecular Medical SciencesUniversity of Nottingham, Nottingham University HospitalsNottinghamUK

Personalised recommendations